SUPPLEMENTARY MATERIAL
APPENDIX

Appendix 1. Members of the Register of Severe Asthma of the Region of Murcia Group

REgistro de Asma GRAve de la Región de MURcia (RE-ASGRAMUR)

Steering Committee

Manuel Castilla Martínez (Hospital Universitario Los Arcos del Mar Menor, San Javier), Juan Carlos Miralles López (Hospital Universitario Reina Sofía, Murcia), José Valverde Molina (Hospital General Universitario Santa Lucía, Cartagena)

Investigators

Manuel Castilla Martínez, José Valverde Molina, Yaiza Isabel Bonilla Pacheco (Hospital Universitario Los Arcos del Mar Menor, San Javier), Loreto Alemany Francés, Ana Mora González (Hospital General Universitario Morales Meseguer, Murcia), Miguel Henrique Reyes Cotes, María Karina Magdalena Bethencourt (Hospital Comarcal del Noroeste, Caravaca), Sheila Cabrejos Perotti, El Molaka Zouhair (Hospital General Universitario Rafael Méndez, Lorca), Juan Carlos Miralles López, María Jesús Avilés Inglés (Hospital General Universitario Reina Sofía, Murcia), Isabel Flores Martín, Javier Bravo Gutiérrez, Rocío Ibáñez Meléndez, Carolina Díaz García (Hospital General Universitario Santa Lucía, Cartagena), Manuel José Pajarón Fernández, Vanesa Alonso Cogny (Hospital Comarca La Vega, Cieza), Rubén Andújar Espinosa, José Meseguer Arce, Mariola Navarro Guerrero (Hospital Clínico Universitario Virgen de la Arrixaca, Murcia)

Appendix 2. Methods

We recorded the following characteristics: age, time with disease, personal history (comorbidities), type 2 biomarkers, and previous systemic/biological treatments. Disease control was assessed based on the Asthma Control Test (ACT), use of oral corticosteroids, and prebronchodilator forced expiratory volume in the first second (prebronchodilator FEV_1) scores at baseline, and at follow-up weeks 4 and 12.

Dupilumab was prescribed following the approved dosage: initial dose of 600 mg and then 300 mg every 2 weeks in patients taking long-term oral corticosteroids use or any relevant type 2 comorbidity, or 400 mg and then 200 mg every 2 weeks in the remaining patients. This study complied with guidelines on the indication of dupilumab, which was funded by the Spanish Agency of Medicines and Medical Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS). The treatment effect was monitored according to regulations.

Lung function was measured according to the reference values and z score set out in the guidelines of the Spanish Society of Pulmonology and Thoracic Surgery.

Fractional exhaled nitric oxide was measured using a NioxVero electrochemical analyzer according to standard procedures.

The diagnosis of polyposis was established using nasal endoscopy and/or sinus computed tomography.

The presence of atopy was established based on positive skin test or specific IgE results.